Skip to content
#gene editing Review

CRISPR–cas systems in pharmacology: functional pharmacogenomics, drug screening, resistance, and therapeutic translation

Sep 2026 · Functional & Integrative Genomics · Vol 26 · 0 citations · 160 references
Medicine

TL;DR

Overall, CRISPR-Cas9 represents a vital platform for future pharmacological innovation, but its broad clinical use may require further validation of safety, efficacy, durability, and accessibility.

View source

Similar papers

Review Open access Aug 2026

CRISPR-Cas9 gene editing approaches in colorectal cancer: Current progress and future prospects.

Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide, characterized by genetic heterogeneity and the accumulation of mutations in key oncogenes and tumor suppressor genes. CRISPR-Cas9 technology has greatly advanced genetic research by enabling precise genome editing. This review focuses on the innovative applications of CRISPR-Cas9 in CRC research, particularly its role in identifying novel therapeutic targets, elucidating mechanisms of drug resistance, and uncovering metabolic and stem cell pathway alterations in tumorigenesis. We highlight the diverse CRISPR systems, including Cas9, Cas12, Cas13, and advanced variants such as CRISPR activation (CRISPRa), CRISPR interference (CRISPRi), base editing, and prime editing, which have expanded gene knockout studies and enhanced our understanding of CRC. Despite these breakthroughs, challenges such as off-target effects and delivery limitations remain. Ongoing efforts to refine CRISPR technology aim to enhance its precision and clinical applicability, ultimately paving the way for more effective and personalized treatment strategies for CRC. In this review, we explore these advances and focus on the latest developments in CRISPR-based approaches for CRC treatment.

Mohadeseh Hassannia, P. Amirifar · 0 citations
Review Aug 2026

Exploring the Potential of CRISPR-Cas9 in Carcinoma Therapy: Advances, Challenges and Future Perspectives.

Gene editing has enormous potential in biomedical fields, including cancer and personalized medicine. CRISPR-Cas9 is a gene-editing system in which the Cas9 enzyme, guided by RNA derived from short palindromic repeats, alters DNA sequences to inhibit oncogenes through base and prime editing, thereby suppressing tumor growth. Despite significant advancements in anticancer therapies, limitations such as off-target effects, ethical concerns, and challenges in targeted delivery restrict its potential clinical applications. In the present review, we explore the mechanisms of CRISPR-Cas9 gene editing, recent technological advancements, and prospects for cancer management. We also provide insights into strategies for precise delivery, improved targeting accuracy, and the regulatory considerations surrounding CRISPR-Cas9 for oncological applications. Additionally, this review examines the potential of CRISPR-Cas9 in personalized cancer therapy and discusses approaches to enhance tumor-specific targeting and facilitate clinical translation.

Nikhil Rawal, Shruti Batra, Tanu Sharma et al. · 0 citations
Review Open access Sep 2026

Recent Advances in CRISPR/Cas Technologies for Biological Discovery, Therapeutics, and Diagnostics

The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein (Cas) system began as a tool for programmable genome editing. CRISPR/ Cas technologies have evolved into a versatile platform for functional genomic screening, epigenome editing, therapeutic target discovery, and highly sensitive molecular diagnostics. New effectors and engineered variants continue to push these applications into personalized medicine and point-of-care testing. Here, this review highlights recent advances in therapeutic target discovery and therapeutic and molecular diagnostic development utilizing CRISPR/Cas technologies. We discuss how CRISPR interference (CRISPRi), CRISPR activation (CRISPRa), base editing, and prime editing have improved our understanding of disease mechanisms, while creating new opportunities for therapeutic intervention. Current applications in cancer immunotherapy, infectious disease, and neurological disorders are also discussed. In diagnostics, CRISPR-based platforms enable sensitive detection of infectious pathogens, cancer biomarkers, and genetic disorders using programmable nuclease activity in both laboratory and point-of-care settings. Collectively, these advances continue to expand the role of CRISPR/Cas technology across biological discovery, disease diagnostics, and therapeutic development, driving progress in precision medicine.

Moon-Soo Kim, Hae Sol Do, H. Jang et al. · 0 citations
Review Open access Jul 2026

CRISPR-Based Genome Editing in Contemporary Clinical Medicine: Therapeutic Translation, Global Challenges and the Future of Precision Medicine

CRISPR has progressed from an experimental genome-engineering technology to a clinically relevant therapeutic platform, although its future impact will depend on the ability to combine molecular precision and durable therapeutic benefit with rigorous safety assessment, responsible governance, and equitable access across diverse populations and healthcare systems.

Gabriel Alejandro Ortega Moreno, Gerardo Amaya Villagran, A. González et al. · 0 citations
#gene editing Open access Sep 2026

CRISPR-Based Gene Editing in Human and Animal Health: Revolutionizing Disease Resistance and Treatment

CRISPR gene-editing technology has revolutionized modern genetics, offering precise and efficient modifications across multiple domains, including human medicine, agriculture, and veterinary science. This study explores the diverse applications of CRISPR, highlighting its role in treating genetic disorders such as sickle cell anemia and Duchenne muscular dystrophy, advancing cancer immunotherapies, and developing CRISPR-based antiviral therapies for HIV and COVID-19. In agriculture, CRISPR has facilitated the development of disease-resistant livestock, enhanced crop yields, and improved food sustainability. Additionally, CRISPR is being integrated with artificial intelligence (AI) and bioinformatics to optimize gene-editing accuracy, predict off-target effects, and accelerate drug discovery. Despite these advancements, CRISPR faces significant challenges, including ethical dilemmas surrounding germline editing, regulatory inconsistencies across countries, high costs of gene therapies, and concerns about genetic inequality. The legal and social implications of CRISPR remain complex, requiring global cooperation to establish standardized regulations and ensure equitable access to genetic therapies. Emerging innovations such as base editing, prime editing, and epigenetic modifications offer promising solutions to improve CRISPR’s precision and safety. Looking ahead, CRISPR’s long-term success will depend on responsible scientific advancements, ethical oversight, and public acceptance. With the continued refinement of gene-editing techniques and AI-driven CRISPR optimizations, this technology holds the potential to revolutionize medicine, agriculture, and environmental conservation. However, careful implementation and transparent discussions are essential to navigate the ethical, legal, and societal challenges that accompany CRISPR’s rapid development.

B. Aloufi · 0 citations

Related blog posts

GPT-Lab Sep 17, 2026

Beyond Prompt Engineering: The Role of Tacit Knowledge in Software Engineering

AI is making software generation faster, but speed does not remove the need for expertise. As more work is delegated to AI, tacit knowledge may become one of the most important human advantages in software engineering. The post Beyond Prompt Engineering: The Role of Tacit Knowledge in Software Engineering appeared first on GPT-Lab.

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.